The Endometrial Receptivity Analysis (ERA) test, offered by Igenomix, uses a sophisticated genetic analysis of endometrial tissue to assess its receptivity for embryo implantation. This involves analyzing the expression of 248 genes related to endometrial receptivity, providing a personalized window of implantation (WOI). This personalized WOI allows for a more precise timing of embryo transfer during in vitro fertilization (IVF), optimizing the chances of successful implantation and pregnancy.
Determining the optimal WOI is crucial for IVF success. Traditional methods for evaluating endometrial receptivity, such as ultrasound and hormone level measurements, offer limited insight. This personalized genetic assessment addresses this limitation, potentially improving implantation rates and reducing the emotional and financial burdens associated with repeated IVF cycles. The development and application of this technology represent a significant advancement in personalized reproductive medicine, moving beyond generalized assessments towards a more precise, patient-specific approach.
